Optimising Assessments of the Epidemiological Impact in the Netherlands of Paediatric Immunisation with 13-Valent Pneumococcal Conjugate Vaccine Using Dynamic Transmission Modelling

Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol

(2013) Roman Prymula et al.   VACCINE

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010–2020

(2013) Ruth Link-Gelles et al.   VACCINE

Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

(2012) Raymond A Farkouh et al.   Expert Review of Vaccines

Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales

(2012) Yoon Hong Choi et al.   PLoS One

Cost-effectiveness of pertussis booster vaccination in the Netherlands

(2012) Mark H. Rozenbaum et al.   VACCINE

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

(2012) Albert Jan van Hoek et al.   VACCINE

Serotype replacement in disease after pneumococcal vaccination

(2011) Daniel M Weinberger et al.   LANCET

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

(2011) Elizabeth Miller et al.   LANCET INFECTIOUS DISEASES

7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?

(2011) Yoon Hong Choi et al.   PLoS One

Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

(2011) Roman Prymula et al.   VACCINE

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

(2011) Elizabeth Miller et al.   VACCINE

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease

(2010) Alessia Melegaro et al.   BMC INFECTIOUS DISEASES

Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model

(2010) Robin de Vries et al.   PLoS One

Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008

(2010) E. Koshy et al.   THORAX

Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar®)

(2010) Mark H. Rozenbaum et al.   VACCINE

Effect of Reduced-Dose Schedules With 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Pneumococcal Carriage in Children

(2009) Elske J. M. van Gils et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials

(2009) Roman Prymula et al.   LANCET

Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases

(2008) Joël Mossong et al.   PLOS MEDICINE

Cost-Utility of Repeated Screening for Chlamydia Trachomatis

(2007) Robin de Vries et al.   VALUE IN HEALTH